Interim infection prevention and control recommendations for hospitalized patients with Middle East Respiratory syndrome coronavirus (MERS-CoV)
Published Date:May 14, 2014
Corporate Authors:Centers for Disease Control and Prevention (U.S.)
Disease Transmission, Infectious/prevention & Control
Middle East Respiratory Syndrome Coronavirus
Respiratory Tract Infections
Description:Standard, contact, and airborne precautions are recommended for management of hospitalized patients with known or suspected MERS-CoV infection, based on CDC's case definition for a patient under investigation: www.cdc.gov/coronavirus/mers/case-def.html#pui. Note that additional infection prevention precautions or considerations may be needed if a MERS-CoV patient has other conditions or illnesses that warrant specific measures (e.g., tuberculosis, Clostridium difficile, multi-drug resistant organisms).
Though these recommendations focus on the hospital setting, the recommendations for personal protective equipment (PPE), source control (i.e., placing a facemask on potentially infected patients when outside of an airborne infection isolation room), and environmental infection control measures are applicable to any healthcare setting.
In this guidance healthcare personnel (HCP) refers all persons, paid and unpaid, working in healthcare settings who have the potential for exposure to patients and/or to infectious materials, including body substances, contaminated medical supplies and equipment, contaminated environmental surfaces, or contaminated air. HCP include, but are not limited to, physicians, nurses, nursing assistants, therapists, technicians, emergency medical service personnel, dental personnel, pharmacists, laboratory personnel, autopsy personnel, students and trainees, contractual personnel, home healthcare personnel, and persons not directly involved in patient care (e.g., clerical, dietary, house-keeping, laundry, security, maintenance, billing, chaplains, and volunteers) but potentially exposed to infectious agents that can be transmitted to and from HCP and patients. This guidance is not intended to apply to persons outside of healthcare settings.
As information becomes available, these recommendations will be re-evaluated and updated as needed. These recommendations are based upon available information (as of May 14, 2014) and the following considerations:
• Suspected high rate of morbidity and mortality among infected patients
• Evidence of limited human-to-human transmission
• Poorly characterized clinical signs and symptoms
• Unknown modes of transmission of MERS-CoV
• Lack of a vaccine and chemoprophylaxis
Supporting Files:No Additional Files
You May Also Like: